UA95636C2 - Improved sgp 130fc dimers - Google Patents

Improved sgp 130fc dimers

Info

Publication number
UA95636C2
UA95636C2 UAA200814839A UAA200814839A UA95636C2 UA 95636 C2 UA95636 C2 UA 95636C2 UA A200814839 A UAA200814839 A UA A200814839A UA A200814839 A UAA200814839 A UA A200814839A UA 95636 C2 UA95636 C2 UA 95636C2
Authority
UA
Ukraine
Prior art keywords
polypeptide dimer
relates
domain
amino acid
pharmaceutical composition
Prior art date
Application number
UAA200814839A
Other languages
English (en)
Ukrainian (uk)
Inventor
Георг Вьотзиг
Дирк Сигерт
Original Assignee
Конарис Рисерч Инстит'Ют Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Конарис Рисерч Инстит'Ют Аг filed Critical Конарис Рисерч Инстит'Ют Аг
Publication of UA95636C2 publication Critical patent/UA95636C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к полипетидному димеру, способному ингибировать активность агонистического комплекса IL-6/sIL-6R, который содержит два мономера, где каждый из указанных мономеров содержит внешне клеточную часть молекулы gp130 или ее вариант или фрагмент, конденсированный с доменом Fc белка IgGl, и где по крайней мере один аминокислотный остаток Leuшарнирной области домена Fc заменяют на по крайней мере один гидрофильный аминокислотный остаток. Изобретение также относится к вектору экспрессии, содержащему заявленный полинуклеотид, клетке-хозяину, содержащей указанный вектор экспрессии. Также описаны способ получения заявленного полипептидного димера и фармацевтическая композиция, содержащая заявленный полипептидный димер. Кроме того изобретение относится к применению заявленного полипептидного димера для по
UAA200814839A 2006-06-30 2007-06-29 Improved sgp 130fc dimers UA95636C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06013668A EP1873166B1 (en) 2006-06-30 2006-06-30 Improved sgp 130Fc dimers

Publications (1)

Publication Number Publication Date
UA95636C2 true UA95636C2 (en) 2011-08-25

Family

ID=37654867

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200814839A UA95636C2 (en) 2006-06-30 2007-06-29 Improved sgp 130fc dimers

Country Status (21)

Country Link
US (3) US8895012B2 (ru)
EP (1) EP1873166B1 (ru)
JP (1) JP5417171B2 (ru)
KR (1) KR101474817B1 (ru)
CN (1) CN101484472B (ru)
AT (1) ATE480568T1 (ru)
AU (1) AU2007263939B2 (ru)
BR (1) BRPI0713063B8 (ru)
CA (1) CA2656440C (ru)
CY (1) CY1110973T1 (ru)
DE (1) DE602006016765D1 (ru)
DK (1) DK1873166T3 (ru)
EA (1) EA015620B1 (ru)
ES (1) ES2352561T3 (ru)
HR (1) HRP20100663T1 (ru)
PL (1) PL1873166T3 (ru)
PT (1) PT1873166E (ru)
RS (1) RS51544B (ru)
SI (1) SI1873166T1 (ru)
UA (1) UA95636C2 (ru)
WO (1) WO2008000516A2 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
CA2690825C (en) 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
EP2050759A1 (en) * 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
KR20140020228A (ko) * 2010-09-21 2014-02-18 알토 바이오사이언스 코포레이션 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP3139660B1 (en) * 2013-09-20 2021-01-20 Intel Corporation Ap location query
EP3673915A1 (en) 2014-06-30 2020-07-01 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
MA41116A (fr) * 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
DK3226888T3 (da) * 2014-12-01 2021-07-12 Ferring Bv Administration af en selektiv inhibitor af il-6-trans-signalering
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3529263A4 (en) 2016-10-21 2020-07-08 Altor BioScience Corporation MULTIMERIC MOLECULES BASED ON IL-15
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
BR112022025166A2 (pt) 2020-06-10 2022-12-27 Ferring Bv Composto farmacêutico para o tratamento de doença cardiovascular aterosclerótica
WO2022139580A1 (en) 2020-12-22 2022-06-30 Ferring B.V. Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
CN118043639A (zh) * 2021-09-01 2024-05-14 泰利斯制药(创新)有限公司 聚集体分离方法
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
PL199659B1 (pl) * 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
ES2269366T3 (es) * 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60037648T2 (de) * 2000-04-21 2010-06-17 Conaris Research Institute Ag Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
KR20030097876A (ko) 2001-05-21 2003-12-31 넥타르 테라퓨틱스 화학적으로 개질된 인슐린의 폐 투여
US7507412B2 (en) * 2001-07-18 2009-03-24 Merck Patent Gmbh Glycoprotein VI fusion proteins
AU2002356511A1 (en) * 2001-07-30 2003-04-01 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
CA2526169A1 (en) * 2003-06-12 2004-12-23 Eli Lilly And Company Fusion proteins
EP1491554A1 (en) 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
PT1630232E (pt) 2004-08-27 2008-10-02 Conaris Res Inst Ag Sequências de nucleótidos optimizadas que codificam sgp130
EP1801121A1 (en) 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere

Also Published As

Publication number Publication date
EP1873166B1 (en) 2010-09-08
ES2352561T3 (es) 2011-02-21
US20100028367A1 (en) 2010-02-04
US9573989B2 (en) 2017-02-21
CN101484472A (zh) 2009-07-15
HRP20100663T1 (hr) 2011-01-31
WO2008000516A3 (en) 2008-03-27
WO2008000516B1 (en) 2008-05-08
AU2007263939B2 (en) 2011-11-24
JP2009540843A (ja) 2009-11-26
PL1873166T3 (pl) 2011-03-31
WO2008000516A2 (en) 2008-01-03
CY1110973T1 (el) 2015-06-11
AU2007263939A1 (en) 2008-01-03
CN101484472B (zh) 2013-07-24
CA2656440C (en) 2018-10-02
US9034817B2 (en) 2015-05-19
EA200802396A1 (ru) 2009-06-30
EP1873166A1 (en) 2008-01-02
US20140178378A1 (en) 2014-06-26
DK1873166T3 (da) 2010-12-20
KR101474817B1 (ko) 2014-12-22
BRPI0713063B1 (pt) 2019-10-08
SI1873166T1 (sl) 2011-01-31
US8895012B2 (en) 2014-11-25
PT1873166E (pt) 2010-12-09
RS51544B (en) 2011-06-30
EA015620B1 (ru) 2011-10-31
US20150361157A1 (en) 2015-12-17
KR20090037898A (ko) 2009-04-16
CA2656440A1 (en) 2008-01-03
DE602006016765D1 (de) 2010-10-21
BRPI0713063B8 (pt) 2021-05-25
JP5417171B2 (ja) 2014-02-12
BRPI0713063A2 (pt) 2012-04-17
ATE480568T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
UA95636C2 (en) Improved sgp 130fc dimers
US10570206B2 (en) Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereof
US20230151072A1 (en) Masked il-2 cytokines and their cleavage products
IL296913A (en) Il-12 masked cytokines and their cleavage products
WO2008090958A1 (ja) ドメイン交換された遺伝子組換え抗体組成物
HRP20151227T1 (hr) Sastavi i postupci uporabe za terapeutska protutijela
WO2008090960A1 (ja) ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
EP2964676A1 (en) Anti-c-met tandem fc bispecific antibodies
AU2015330087A1 (en) Combination therapy of bispecific antibodies specific for FAP and DR5 and chemotherapeutic agents
KR20220161406A (ko) 마스킹된 il-15 사이토카인 및 이들의 절단 산물
EP2282757B1 (en) Neutralization of gm-csf for the treatment of heart failure
EP2245062B1 (en) Methods of treating bone-loss disorders using a gm-csf antagonist
CA3190417A1 (en) Compositions and methods related to receptor pairings
US20230049152A1 (en) Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
EP4251187A2 (en) Tumor-specific cleavable linkers
WO2021003465A1 (en) Sialidase-her2-antibody fusion proteins and methods of use thereof
US20230257453A1 (en) Collagen-targeted fusion proteins and antibodies
WO2022047243A1 (en) Methods and compositions to treat autoimmune diseases and cancer
US20220288226A1 (en) Methods and compositions to treat autoimmune diseases and cancer
WO2022031882A1 (en) Il-8 antibodies and methods of use thereof
KR20230117348A (ko) Tgf-베타 계열의 다중 리간드를 저해할 수 있는 신규한 이작용성 다중특이적 길항제 및 이의 용도
WO2012142083A3 (en) C1q/tnf-related protein 12 and compositions and methods of using same